Lakeside

Quanome Technologies, Inc. operates in three main business areas. First, it has established, revenue-generating pharmaceutical distribution operations through its subsidiary, Hupan Pharmaceutical. This segment primarily sells infusion products, foods for special medical purposes, and specialty pharmaceuticals to hospitals, pharmaceutical distributors, and other healthcare providers. Second, the company has a recently initiated strategic focus on quantum-related and certain other advanced technology activities. This area is currently in the development and evaluation stage and has not generated revenue as of the date of this report. Third, Quanome Technologies, Inc. has recently started efforts to provide dedicated AI compute capacity and managed inference services. These efforts are in the preliminary stage and have not resulted in executed customer contracts or generated revenue as of the date of this report. Prior to February 12, 2026, the company also operated as a U.S.-based integrated cross-border supply chain solutions provider focused on the Asian market, in addition to its pharmaceutical distribution. On February 12, 2026, the operations of ABL Chicago were transferred to an unrelated third party, and the company ceased substantive involvement in ABL Chicago's cross-border freight forwarding and logistics business. The company is evaluating opportunities to reposition its business from traditional pharmaceutical distribution toward quantum-related technologies and applications, including quantum computing, artificial intelligence, advanced simulation, and intelligent systems, through its subsidiary, Quantum Nexus. Quantum Nexus is evaluating and developing computational capabilities with potential applications in therapeutic discovery, healthcare, advanced materials, energy, and cybersecurity. The company may also pursue collaborations, acquisitions, or other strategic transactions in these fields.